| dc.contributor.author |
Terpos, E |
en |
| dc.contributor.author |
Verrou, E |
en |
| dc.contributor.author |
Banti, A |
en |
| dc.contributor.author |
Kaloutsi, V |
en |
| dc.contributor.author |
Lazaridou, A |
en |
| dc.contributor.author |
Zervas, K |
en |
| dc.date.accessioned |
2014-06-06T06:47:30Z |
|
| dc.date.available |
2014-06-06T06:47:30Z |
|
| dc.date.issued |
2007 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1016/j.leukres.2006.05.018 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/3639 |
|
| dc.subject |
myelodysplastic syndrome |
en |
| dc.subject |
Proteasome Inhibitor |
en |
| dc.subject |
Bone Marrow |
en |
| dc.title |
Bortezomib is an effective agent for MDS/MPD syndrome with 5q− anomaly and thrombocytosis |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1016/j.leukres.2006.05.018 |
en |
| heal.publicationDate |
2007 |
en |
| heal.abstract |
Thrombocytosis is not a frequent event in myelodysplasia (MDS) and is observed mainly in 5q− syndrome and MDS/myeloproliferative (MPD) overlap syndromes. The pathogenetic mechanism of thrombocytosis in 5q− has not been fully elucidated to-date. Bortezomib is a proteasome inhibitor which seems to be effective in MDS. We present here the first case in the literature with MDS/MPD syndrome, sole 5q− |
en |
| heal.journalName |
Leukemia Research |
en |
| dc.identifier.doi |
10.1016/j.leukres.2006.05.018 |
en |